All results
19 results for biomarkers als
-
REBIRTH
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of…
- Ages
- 18 Years - N/A
- Sexes
- Female
-
Study in Parkinson Disease of Exercise (SPARX3)
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified…
- Ages
- 40 Years - 80 Years
- Sexes
- All
-
Study of XL092 in Comb. with Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor…
- Ages
- 18 Years - N/A
- Sexes
- All
-
TAPUR: Testing FDA Approved Drugs That Target Specific Abnormal Tumor Genes in Pts w/Advanced Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a…
- Ages
- 12 Years - N/A
- Sexes
- All
-
TRACK-FA
This is a natural history study prospectively investigating neuroimaging markers of disease progression in children and adults with Friedreich ataxia (FA).…
- Ages
- 5 Years - N/A
- Sexes
- All
-
Takeda TAK-999-3001
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Testing Triapine w/ Targeted Radiation-based LU177 vs Lu177 alone in pts w/ metastatic NETs
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
VITALISScE
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called…
- Ages
- 18 Years - N/A
- Sexes
- All